Anti-Mouse myeloperoxidase/MPO Antibody (6G4)
Based on 1 publication(s) in Google Scholar
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV).
For research use only. We do not sell to patients.
- Purity : 97.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse myeloperoxidase/MPO Antibody (6G4)
More
Biological Activity
Description
Isotype
Mouse IgG2c kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
myeloperoxidase/MPO
In Vitro
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) (5 μg/mL, 30 min) can bind to the extracellular DNA released by activated neutrophils to form DNA/MPO/IgG immune complexes in neutrophils from bone marrow of C57BL/6J mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) (1 mg, i.p., single dose) successfully establishes a novel mouse model of pulmonary vasculitis in female C57BL/6J mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6J mice (8-10 weeks)[1]
-
Dosage:0.75 mg, combined with anti-rat glomerular basement membrane serum (100 μL, i.v., on day 0), anti-MPO mAb (6D1) (0.75 mg) and LPS (0.5 μg/g) (HY-D1056)
-
Administration:Intraperitoneal injection (i.p.), single dose on day 5
-
Result:Caused 70% of glomerular necrosis or crescent formation during the acute phase.
Caused 70% of glomerular scarring during the chronic phase.
Increased the infiltration of neutrophils and macrophages in the acute phase and T cells in the chronic phase.
Significantly upregulated inflammatory factors and ECM molecules.
-
Animal Model:Female C57BL/6J mice (8-12 weeks)[2]
-
Dosage:1 mg, combined with fMLP (10 μg, intratracheal injection (i.t.)) (HY-P0224), LPS (10 μg, intratracheal injection (i.t.)) (HY-D1056) and anti-MPO mAb (6D1) (0.5 mg)
-
Administration:Intraperitoneal injection (i.p.), single dose
-
Result:Relied on the cGAS/STING/IFN-I pathway to synergistically induce severe pulmonary hemorrhage and inflammation with bacterial ligands.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo administration; in vitro administration; Immunofluorescence
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse myeloperoxidase/MPO Antibody (6G4)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Parasit Vectors
Pentatrichomonas hominis induces extracellular traps formation of macrophages via the TLR2/NADPH/PAD4 pathway. [Abstract]2025 Jul 1;18(1):248. PMID: 40598534
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Fayçal CA, et al. An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition. Matrix Biol. 2022 Feb;106:12-33. [Content Brief]
[2]. Kessler N, et al. Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing. J Exp Med. 2022 Oct 3;219(10):e20220759. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) Related Classifications
HY-P990181 Related Classifications
Powered by Bioz